Biocure Technology Inc.

Recent News

  • BiocurePharm, Korea ("BPK") Announces Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - January 20, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK ...

    2020-01-20 9:00 AM ET
  • BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing

    Vancouver, British Columbia--(Newsfile Corp. - December 5, 2019) - BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has closed its Convertible Debenture financing. BPK has issued convertible debentures for gross proceeds of ...

    2019-12-05 9:00 AM ET
  • Biocure Enters into a Clinical Trial for CAR T -Cell Products in Korea

    Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has appointed CLIPS (Clinical Professional Services) as the CRO (Contract Research Organization) to proceed with a ...

    2019-10-17 8:00 AM ET
  • CORRECTION FROM SOURCE: BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing

    Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") wishes to correct its earlier press release of today's date to advise that it has closed its Convertible Debenture financing through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued convertible ...

    2019-09-19 8:37 PM ET
  • BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing

    Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has closed its Convertible Debenture financing through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has ...

    2019-09-19 8:00 AM ET
  • BiocurePharm, Korea ("BPK") Announces Closing of Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, ...

    2019-07-11 5:14 PM ET
  • Biocure Enters into Exclusive Joint R&D Agreement with Pharos Vaccine Inc. for Overseas Market of CAR T-Cell Products

    Vancouver, British Columbia--(Newsfile Corp. - May 16, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (formerly Gravis Energy Corp.) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has entered into an agreement with Pharos Vaccine Inc. for the development of ...

    2019-05-16 7:40 AM ET
  • Biocure Announces the Appointment of a New Director

    Vancouver, British Columbia--(Newsfile Corp. - March 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that effective of today's date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc.After completing a PhD in Biochemistry at Texas A&M ...

    2019-03-14 8:00 AM ET